Download PDF
Kardiologie up2date 2013; 09(02): 80-86
DOI: 10.1055/s-0033-1344185
Hotline – Herzrhythmusstörungen
© Georg Thieme Verlag KG Stuttgart · New York

Antikoagulation bei Vorhofflimmern – Dabigatran, Rivaroxaban oder Apixaban – die Qual der Wahl?

Armin Luik
,
Claus Schmitt
,
Andrea Radzewitz
Further Information

Publication History

Publication Date:
08 July 2013 (online)

Also available at
    Permissions and Reprints All articles of this category

Corrected by:

Antikoagulation bei Vorhofflimmern – Dabigatran, Rivaroxaban oder Apixaban – die Qual der Wahl?Kardiologie up2date 2013; 09(03): 252-252
DOI: 10.1055/s-0033-1353586

Abstract

New oral anticoagulation agents (NOACs) have definitively widened the existing spectrum of antithrombotic prophylaxis and therapy. NOACs (dabigatran etexilate, rivaroxaban, apixaban) can be given at fixed doses without coagulation monitoring. They show additional advantages in comparison with the mainly used vitamin K antagonists. Oral anticoagulation with NOACs has to be initiated and monitored carefully and patient- and disease-specific factors have to be taken into account. This article summarizes published clinical trial data related to dabigatran, apixaban and rivaroxaban. We will discuss special aspects and further more how to manage emergency situations associated with the NOACs.

 

  • Literatur

  • 1 Ruff CT, Giugliano RP, Antman EM et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). AHJ 2010; 160: 635-641
    CrossrefPubMedSearch in Google Scholar
  • 2 Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annual review of medicine 2011; 62: 41-57
    CrossrefPubMedSearch in Google Scholar
  • 3 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEJM 2009; 361: 1139-1151
    CrossrefPubMedSearch in Google Scholar
  • 4 Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. NEJM 2011; 365: 981-992
    CrossrefPubMedSearch in Google Scholar
  • 5 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEJM 2011; 365: 883-891
    CrossrefPubMedSearch in Google Scholar
  • 6 Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. NEJM 2011; 364: 806-817
    CrossrefPubMedSearch in Google Scholar
  • 7 Uchino KHAV. Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402
    CrossrefPubMedSearch in Google Scholar
  • 8 Hohnloser SH, Oldgren J, Yang S et al. Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation 2012; 125: 669-676
    CrossrefPubMedSearch in Google Scholar
  • 9 Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372
    CrossrefPubMedSearch in Google Scholar
  • 10 Boehringer Ingelheim. Fachinformation Pradaxa 150 mg Hartkapseln. 2012
    PubMedSearch in Google Scholar
  • 11 HealthCare B. Fachinformation des Arzneimittel-Kompendiums der Schweiz: Xareltro. 2012
    PubMedSearch in Google Scholar
  • 12 Fachinformation ELIQUIS 2,5 mg Filmtabletten. 2011
    PubMedSearch in Google Scholar
  • 13 Lip GY, Larsen TB, Skjoth F et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Card 2012; 60: 738-746
    CrossrefPubMedSearch in Google Scholar
  • 14 Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747
    CrossrefPubMedSearch in Google Scholar
  • 15 Komocsi A, Vorobcsuk A, Kehl D et al. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 1537-1545
    CrossrefPubMedSearch in Google Scholar
  • 16 Mega JL, Braunwald E, Murphy SA et al. Rivaroxaban in Patients Stabilized after a ST-Elevation Myocardial Infarction: Results from the ATLAS ACS 2-TIMI 51 Trial. J Am Coll Card 2013;
    PubMedSearch in Google Scholar
  • 17 Lip GY, Durrani OM, Roldan V et al. Peri-operative management of ophthalmic patients taking antithrombotic therapy. Int J Clin Practice 2011; 65: 361-371
    CrossrefPubMedSearch in Google Scholar
  • 18 Dewilde WJ, Oirbans T, Verheugt FW et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115
    CrossrefPubMedSearch in Google Scholar
  • 19 Steiner T. Neue direkte orale Antikoagulanzien: Was im Notfall zu beachten ist. Dtsch Arztebl International 2012; 109: 1928-1930
    PubMedSearch in Google Scholar
  • 20 Österreichische Gesellschaft für Laboratoriumsmedizin und Klinische Chemie. Neue Orale Antikoagulantien. 2013 http://www.oeglmkc.at/oak (27.02.2013)
    PubMedSearch in Google Scholar
  • 21 BfARM – Bundesinstitut für Arzneimittel und Medizinprodukte. Hinweise zum Umgang mit Blutungen unter Dabigatran (Pradaxa). 2012
    PubMedSearch in Google Scholar